TY - JOUR
T1 - Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis
AU - Yamaoka, Toshifumi
AU - Ogawa, Fumihide
AU - Muroi, Eiji
AU - Hara, Toshihide
AU - Komura, Kazuhiro
AU - Iwata, Yohei
AU - Takenaka, Motoi
AU - Shimizu, Kazuhiro
AU - Hasegawa, Minoru
AU - Fujimoto, Manabu
AU - Sato, Shinichi
PY - 2008/11
Y1 - 2008/11
N2 - Background: Systemic sclerosis (SSc) is characterized by autoantibodies against various cellular components. Objective: To determine the presence or levels of antibodies (Abs) against a protease domain (PD) of caspase-8 and their clinical relevance in SSc. Methods: Anti-caspase-8 PD Ab was examined by enzyme-linked immunosorbent assay and immunoblotting using human recombinant caspase-8 PD. Caspase-8 activity was evaluated by spectrophotometric detection of cleavage from p-nitroanilide-labeled IETD, a substrate of caspase-8. Results: IgG anti-caspase-8 PD Ab levels in patients with SSc, systemic lupus erythematosus, or dermatomyositis were higher than in normal controls (CTL). Furthermore, anti-caspase-8 PD Ab levels in limited cutaneous SSc (lSSc) patients were elevated compared to diffuse cutameous SSc (dSSc) patients. To investigate the clinical correlation, laboratory findings were compared between SSc patients with high levels (>the mean+2SD of CTL) of anti -caspase-8 PD Ab and those with low levels. SSc patients with high levels exhibited lower frequency of male and decreased C-reactive protein levels relative to those with low levels. Immunoblotting showed that anti-caspase-8 PD Ab was present in all SSc patients examined, while it was also detected in 75% of CTL. Caspase-8 activity was inhibited by IgG isolated from sera of SSc patients and CTL, although inhibitory effect was greater in SSc patients than CTL. Conclusion: These results suggest that immune response to caspase-8 occurs in healthy individuals, although it is greater in patients with systemic autoimmune diseases including SSc. Furthermore, high levels of anti-caspase-8 PD Ab may be a serological indicator for a milder SSc subset.
AB - Background: Systemic sclerosis (SSc) is characterized by autoantibodies against various cellular components. Objective: To determine the presence or levels of antibodies (Abs) against a protease domain (PD) of caspase-8 and their clinical relevance in SSc. Methods: Anti-caspase-8 PD Ab was examined by enzyme-linked immunosorbent assay and immunoblotting using human recombinant caspase-8 PD. Caspase-8 activity was evaluated by spectrophotometric detection of cleavage from p-nitroanilide-labeled IETD, a substrate of caspase-8. Results: IgG anti-caspase-8 PD Ab levels in patients with SSc, systemic lupus erythematosus, or dermatomyositis were higher than in normal controls (CTL). Furthermore, anti-caspase-8 PD Ab levels in limited cutaneous SSc (lSSc) patients were elevated compared to diffuse cutameous SSc (dSSc) patients. To investigate the clinical correlation, laboratory findings were compared between SSc patients with high levels (>the mean+2SD of CTL) of anti -caspase-8 PD Ab and those with low levels. SSc patients with high levels exhibited lower frequency of male and decreased C-reactive protein levels relative to those with low levels. Immunoblotting showed that anti-caspase-8 PD Ab was present in all SSc patients examined, while it was also detected in 75% of CTL. Caspase-8 activity was inhibited by IgG isolated from sera of SSc patients and CTL, although inhibitory effect was greater in SSc patients than CTL. Conclusion: These results suggest that immune response to caspase-8 occurs in healthy individuals, although it is greater in patients with systemic autoimmune diseases including SSc. Furthermore, high levels of anti-caspase-8 PD Ab may be a serological indicator for a milder SSc subset.
UR - http://www.scopus.com/inward/record.url?scp=59149085881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59149085881&partnerID=8YFLogxK
M3 - Article
C2 - 19210862
AN - SCOPUS:59149085881
SN - 0392-856X
VL - 26
SP - 998
EP - 1004
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - 6
ER -